Form 4: AbCellera Biologics CEO Carl Hansen Exercises Stock Options and Sells Shares
SEC Form 4 Filing
CEO Carl Hansen exercised stock options and sold a portion of the acquired shares, while also reporting indirect ownership through Thermopylae Holdings Ltd.
Summary
- On May 31, 2024, Carl L. G. Hansen, CEO of AbCellera Biologics Inc., exercised stock options to acquire 56,125 common shares at a price of $2.7 per share.
- Simultaneously, Hansen disposed of 56,125 common shares.
- Following these transactions, Hansen directly owns 8,372,473 share options and indirectly owns 55,802,493 common shares through Thermopylae Holdings Ltd., an entity wholly owned by him.
- The share options vest quarterly over a four-year period, starting November 18, 2021, contingent upon Hansen's continuous service to AbCellera.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option exercises and share sales, indicating a neutral sentiment.
Industry Context
This filing reflects routine transactions by a company insider and is a common occurrence in publicly traded companies. It provides transparency into the executive's holdings and trading activities.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's holdings, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 11/18/2021 | First tranche of share options vested. |
| 05/31/2024 | CEO exercised stock options and disposed of shares. |
| 06/03/2024 | Form 4 filing date. |
| 11/27/2030 | Expiration date of share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.